Vertex Pharmaceuticals (VRTX) Change in Receivables (2009 - 2026)

Vertex Pharmaceuticals has reported Change in Receivables for 18 years, with the latest figure at -$39.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 123.47% year-over-year to -$39.8 million; the trailing twelve-month figure through Mar 2026 stood at $137.9 million (up 697.11% YoY), and the FY2025 full-year result was $347.3 million, up 249.75% from the prior year.
• Change in Receivables for Q1 2026 stood at -$39.8 million, down from $99.4 million in the prior quarter.
• The five-year high for Change in Receivables was $251.6 million in Q1 2024, with the low at -$135.1 million in Q2 2024.
• Average Change in Receivables over 5 years is $50.0 million, with a median of $51.8 million recorded in 2024.
• Peak annual rise in Change in Receivables reached 749.18% in 2024, while the deepest fall reached 4758.62% in 2024.
• Tracing VRTX's Change in Receivables over 5 years: stood at -$10.2 million in 2022, then sank by 50.98% to -$15.4 million in 2023, then sank by 348.05% to -$69.0 million in 2024, then jumped by 244.06% to $99.4 million in 2025, then tumbled by 140.04% to -$39.8 million in 2026.
• The last three Change in Receivables figures came in at -$39.8 million (Q1 2026), $99.4 million (Q4 2025), and $59.9 million (Q3 2025), per Business Quant data.

Peer Comparison